(Bloomberg) — Singapore’s central bank is likely to keep monetary policy unchanged Wednesday as it allows fiscal measures to do the heavy lifting in getting the city-state’s economy back on track.

The Monetary Authority of Singapore, which uses the currency as its main policy tool rather than interest rates, probably will refrain from changing any of the three currency band settings, according to all 19 economists surveyed by Bloomberg.

chart: Singapore Monetary Policy History

© Bloomberg
Singapore Monetary Policy History

The MAS — which typically makes policy decisions twice a year, in April and October — took the unprecedented step in its last announcement of lowering the midpoint of the currency band and reducing the slope to zero. That meant it would allow for a weaker exchange rate to head off deflation and support the export-reliant economy.


Load Error

Since then, the economy has plunged into recession amid the pandemic and the government has unleashed billions of dollars of stimulus to save businesses and jobs. The city-state is slowly starting to shake off the impact of mobility restrictions and exports have continued to gain, but the recovery is likely to be a slow one as international travel restrictions remain and global demand stays weak.

“We’ve not seen the full extent of the crisis” and as much as 20% of the economy will face “deep scarring from which they may not recover,” MAS Managing Director Ravi Menon said Monday during a virtual forum hosted by the Institute of International Finance.

While the city-state has likely seen the worst of the GDP downswing, Menon said non-performing loans and bankruptcies probably will rise through the start of 2021.

The government has forecast a 5%-7% contraction in the economy this year, the worst since independence more than a half-century ago, and may revise that estimate when the Ministry of

On September 8, the troubled Texas-based dining chain Luby’s (LUB) announced its intention to liquidate after a strategic review process launched over the summer. At the time of writing, the shares, though volatile, trade below the lower end of the company’s estimate of $3-4/share upon liquidation (bolding below is mine):

While no assurances can be given, the Company currently estimates, assuming the sale of its assets pursuant to its monetization strategy, that it could make aggregate liquidating distributions to stockholders of between approximately $92 million and $123 million (approximately $3.00 and $4.00 per share of common stock, respectively, based on 30,752,470 shares of common stock outstanding as of September 2, 2020). Aggregate payments will likely be paid in one or more distributions. The Company cannot predict the timing or amount of any such distributions, as uncertainties exist as to the value it may receive upon the sale of assets pursuant to its monetization strategy, the net value of any remaining assets after such sales are completed, the ultimate amount of expenses associated with implementing its monetization strategy, liabilities, operating costs and amounts to be set aside for claims, obligations and provisions during the liquidation and winding-up process and the related timing to complete such transactions and overall process.

Source: Luby’s investor site

Insider Ownership

CEO Christopher Pappas owns over 23% of the shares, and his brother, Harris Pappas, has a similarly large holding. There has been no material insider selling since 2018. Hence, alignment with shareholders is relatively clear. The CEO will benefit far more from an effective, price-maximizing liquidation process than a drawn-out process with high fees.

Value Of Real Estate

That Luby’s has material real estate assets is not new news. There was a Seeking Alpha piece on it two years ago, some good valuation work here, and

The specialist in medical delivery technology, Catalent (CTLT) has been inching higher steadily, as those who are aware about the company’s important role in the availability of a COVID-19 cure have been buying the stock.

While the stock price of better famed peer Emergent BioSolutions (EBS) with three times more followers on Seeking Alpha has also being trending higher, its path has been somewhat more volatile. One of the factors that can explain this volatility is strong following by the retail trading crowd tracking COVID-19 vaccine news.

Figure 1: Comparing stock performance for Catalent and Emergent

ChartData by YCharts

This has not been the case with Catalent despite the company inking three manufacturing agreements with COVID-19 vaccine developers, including big names like Johnson & Johnson’s (NYSE:JNJ), Moderna (NASDAQ:MRNA) and AstraZeneca (NASDAQ:AZN), to provide fill-finish capabilities.

Fill-finish manufacturing

Fill-finish is a lesser-known but crucial step between development of vaccine by biotechs and its availability for clinical trials in testing centers or, at a later stage, on a more widespread basis in hospitals and points of care for administration to patients. Fill-finishing basically involves putting the vaccines in vials or glass containers under strict hygiene or sterile conditions to prevent contamination.

Biotech companies resort to the likes of Catalent for this critical process, as any contamination would adversely impact efficacy of the vaccine and result in significant economic losses for them.

Now, for investors, an important question is whether Catalent will be able to honor its manufacturing contracts with these big names.

The answer is yes, for both drug substance manufacturing and drug product manufacturing capabilities both in the U.S. and Europe. Facilities include Bloomington for Johnson & Johnson and Moderna, as well as Anagni (Italy) for AstraZeneca, but there are other locations too.

Also, the fact that the company

(Bloomberg) — Guolian Securities Co.’s effort to acquire bigger rival Sinolink Securities Co. has ended after the firms couldn’t agree on terms to create a $13 billion Chinese broker in the consolidating industry.

a close up of a man: HAIKOU, CHINA - MAY 09: (CHINA OUT) An investor watches the electronic board at a stock exchange hall on May 9, 2011 in Haikou, Hainan Province of China. The power companies and train markers led Chinese stocks rebounding on Monday. With the benchmark Shanghai Composite Index rose 8.57 points, or 0.3 percent, to close at 2,872.46 points. (Photo by VCG/VCG via Getty Images)

© Photographer: VCG/Getty Images AsiaPac
HAIKOU, CHINA – MAY 09: (CHINA OUT) An investor watches the electronic board at a stock exchange hall on May 9, 2011 in Haikou, Hainan Province of China. The power companies and train markers led Chinese stocks rebounding on Monday. With the benchmark Shanghai Composite Index rose 8.57 points, or 0.3 percent, to close at 2,872.46 points. (Photo by VCG/VCG via Getty Images)

Sinolink had agreed to be bought in an all-stock deal announced Sept. 20, but specific details for the combination couldn’t be agreed to, the companies said in separate but identical stock exchange filings late Monday.

The deal announcement had sent Guolian’s Hong Kong-listed stock soaring as much as 75% on Sept. 21. Shares of Guolian trading in China dropped as much as 5.8% as the market opened on Tuesday, while Sinolink Securities rose as much as 2.9%.

Gallery: These 47 Billionaires Got Richer During The Pandemic (GOBankingRates)

China’s $1.1 trillion securities industry is facing increased pressure as Wall Street firms such as Goldman Sachs Group Inc. and JPMorgan Chase & Co. are allowed to take full control of ventures in the country this year, forcing consolidation.

(Updates with shares in third paragraph)

For more articles like this, please visit us at bloomberg.com

©2020 Bloomberg L.P.

Continue Reading

Source Article

By Sonali Paul

MELBOURNE (Reuters) – Oil prices were steady in early trade on Tuesday, sitting on losses of nearly 3% from the previous session after supplies began to resume in Norway and the U.S. Gulf of Mexico and Libya resumed production at its largest oilfield.

The return of supply comes as resurgent COVID-19 infections in the U.S. Midwest and Europe raise worries about fuel demand growth, posing a challenge for the Organization of Petroleum Exporting Countries and its allies, together called OPEC+.

OPEC+ has curbed supply to help shore up oil prices amid coronavirus pandemic, with cuts of 7.7 million barrels per day due to hold through December. The producers’ market monitoring panel is due to meet next Monday.

“It won’t be a huge surprise if finally the alliance decides to address the worsening situation and amend its action,” Rystad Energy’s head of oil markets, Bjornar Tonhaugen, said in a note.

U.S. West Texas Intermediate (WTI) crude <CLc1> futures inched up 1 cent to $39.44 a barrel at 0117 GMT, while Brent crude <LCOc1> futures rose 2 cents to $41.74 a barrel.

With workers returning to U.S. Gulf of Mexico platforms after Hurricane Delta and Norwegian workers returning to rigs after ending a strike, all eyes were on Libya, a member of the Organization of the Petroleum Exporting Countries (OPEC), which on Sunday lifted force majeure at the Sharara oilfield.

The country’s total output on Monday was at 355,000 bpd and will double if the Sharara field gets back to pumping at the 300,000 bpd it was producing before the Libyan National Army blockaded energy exports in January.

“That would effectively add 0.3% of global oil supply in a very short time frame,” Commonwealth Bank commodities analyst Vivek Dhar said in a note.

Stoking worries about fuel demand, curbs